% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • snta_to_100 snta_to_100 Apr 8, 2014 11:24 AM Flag

    HDCs may be the future of chemotherapy

    Results were presented by Dr. David Gerber of UT Southwestern Medical Center. “Synta’s HDC platform represents an exciting advancement in the field of tumor-targeted delivery,” said Dr. Gerber. “The therapeutic profile of any anti-cancer agent that can be chemically linked to an Hsp90 inhibitor could potentially be enhanced.”

    “The HDC concept is very appealing and has potential to be an important new category of targeted therapy,” stated Dr. David Gandara, Director Thoracic Oncology Program, U.C. Davis Comprehensive Cancer Center, and Chair Lung Cancer Committee of the Southwest Oncology Group (SWOG). “HDCs may be the future of chemotherapy.”

0.38+0.01(+2.70%)May 25 4:00 PMEDT